Baylor University Medical Center at Dallas is a major patient care, teaching and research center for the Southwest and one of the largest medical centers in the Dallas-Fort Worth area. Since 1983, Baylor Dallas has developed an outstanding reputation for patient care and clinical research in blood and marrow transplantation.

Program Highlights
- The Blood and Marrow Transplant (BMT) program at Baylor Charles A. Sammons Cancer Center at Dallas has performed more than 1,800 allogeneic and autologous cell transplants in the past 30 years.
- BMT physicians on the medical staff at Baylor Dallas performed North Texas' first bone marrow transplant in 1983 and Texas' first matched unrelated donor transplant in 1989.
- It is one of the 24 highest volume BMT Centers in the United States based on the number of transplants performed.
- Participation in numerous national clinical trials, including those of the National Institutes of Health Clinical Trials Network and pivotal studies in drug development.
- Among the first programs in the United States to receive accreditation by the Foundation for the Accreditation of Hematopoietic Cell Therapy (FACT) in the United States.
- Is distinguished as a Center of Excellence by multiple insurance carriers.
- Is one of the 20 highest volume BMT Centers in the United States, with more than 10 years of experience.
- In 1982, Dr. Fay established the BMT program at Baylor University Medical Center in San Antonio and the Texas Transplant Institute at the University of Texas. He also served as interim director of the Texas Bone Marrow Transplant and Cellular Therapy Program at UT Southwestern Medical Center.
- In 1989, Dr. Fay joined the medical staff of Baylor University Medical Center and became medical director of the BMT program.
- Dr. Fay was followed by a fellowship in oncology and hematology at Boston University/Boston City Hospital, where he completed his fellowship in hematology.
- He is board certified in internal medicine, hematology, and medical oncology, with more than 20 years of experience.
- He completed his medical education at the University of Puerto Rico School of Medicine and interned in internal medicine at the Veterans Administration Medical Center in San Juan, Puerto Rico. His fellowship in hematology and oncology was completed at the Washington University School of Medicine in St. Louis. He is interested in the treatment of hematologic malignancies and stem cell transplantation and is fluent in Spanish.
- Dr. Vance is board certified in internal medicine, medical oncology and infectious diseases. He completed his medical education, internship and residency at the Johns Hopkins University School of Medicine in Baltimore. He completed fellowships at Harvard Medical School, Dana-Farber Cancer Institute and Brigham and Women's Hospital, while receiving a master of medical science degree from Harvard Manchus Institute of Technology. Dr. Vance joined the staff of Baylor Charles A. Sammons Cancer Center at Dallas in September 1988 from the Dana-Farber Cancer Institute and Harvard School of Public Health.
- In addition to his expertise in internal medicine and infectious diseases, he is an expert in the field of oncology-related infections. He also serves as a specialty clinic in stem cell transplantation, bone marrow transplants at Duke University Medical Center.
- Dr. Piñeiro is board certified in internal medicine and oncology, with more than 20 years of experience. He completed his medical education at the University of Puerto Rico School of Medicine and interned in internal medicine at the Veterans Administration Medical Center in San Juan, Puerto Rico. His fellowship in hematology and oncology was completed at the Washington University School of Medicine in St. Louis. He is interested in the treatment of hematologic malignancies and stem cell transplantation and is fluent in Spanish.

Blood and Marrow Transplant Physicians on the Medical Staff

Edward D. Aguirre, MD
Medical Director, Blood and Marrow Transplant Services
- Dr. Aguirre is board certified in internal medicine, hematology, and medical oncology, with more than 20 years of experience. He graduated from New York University School of Medicine. He completed his residency in internal medicine at New York University School of Medicine. He completed his fellowship in hematopoietic cell transplantation at the Fred Hutchinson Cancer Research Center in Seattle.

R. Brian Berryman, MD
Medical Director, Bone Marrow Transplant Outpatient Clinic
- Dr. Berryman is board certified in internal medicine and medical oncology, with more than 10 years of experience.

Carolina Escobar, MD
- Dr. Escobar is board certified in internal medicine, hematology, and medical oncology. She received her medical education from the Universidad Pontificia Bolivariana and completed her internship and residency at Louisiana State University Health Science Center (LSUHSC). She also completed a fellowship in clinical and experimental hematology at the University of Texas Southwestern Medical Center in Dallas. She completed her fellowship in hematology and oncology at the Fred Hutchinson Cancer Research Center in Seattle.

Joseph W. Tay, MD
Director of Hematopoietic Therapy for Cancer, Baylor Institute for Immunology Research, Hematopoietic Cell Transplantation and Therapeutics, Baylor Research Institute
- Dr. Tay is board certified in internal medicine and medical oncology, with more than 20 years of experience. He is a hematologic oncologist and medical oncologist. He performed research in medical oncology at the University of Colorado School of Medicine. He completed his fellowship at the University of Colorado School of Medicine. He completed his medical education at Washington University School of Medicine in St. Louis, and his fellowship in hematology and oncology was completed at the University of Texas Southwestern Medical Center.

An Introduction for Patients and Families

Baylor Charles A. Sammons Cancer Center at Dallas
Experience and Quality Count

Since its beginning in 1983, the Blood and Marrow Transplant (BMT) program at Baylor Sammons Cancer Center at Dallas has performed more than 5,000 transplants, making it one of the largest BMT programs in the country. The program has seen extraordinary growth in autologous, allogeneic and umbilical cord blood allogeneic transplants.

The BMT program at Baylor Sammons Cancer Center at Dallas focuses on the design and implementation of treatment protocols that use transplantation to treat patients with cancer and benign conditions. The BMT program performs autologous transplants using chemotherapy and/or radiation to the patient to ablate his or her existing cancer cells and medications to boost production of stem cells, which are then transplanted after the ablation has been completed. The ablation and the transplantation may be performed simultaneously or in a sequential manner. The patient then begins a period of recovery and treatment using chemotherapy and/or radiation. The hope is to achieve a complete remission of the disease with transplantation and the use of appropriate chemotherapy and/or radiation.

Supportive Care and Research

At Baylor Sammons Cancer Center at Dallas, we focus on the design and implementation of treatment protocols that use transplantation to treat patients with cancer and benign conditions. The BMT program performs autologous transplants using chemotherapy and/or radiation to the patient to ablate his or her existing cancer cells and medications to boost production of stem cells, which are then transplanted after the ablation has been completed. The ablation and the transplantation may be performed simultaneously or in a sequential manner. The patient then begins a period of recovery and treatment using chemotherapy and/or radiation. The hope is to achieve a complete remission of the disease with transplantation and the use of appropriate chemotherapy and/or radiation.

Reduced Intensity Transplantation Research

As a leader in the field of hematopoietic cell transplantation, Baylor Sammons Cancer Center at Dallas is one of the only programs in the country that focuses on the design and implementation of treatment protocols that use transplantation to treat patients with cancer and benign conditions. The BMT program performs autologous transplants using chemotherapy and/or radiation to the patient to ablate his or her existing cancer cells and medications to boost production of stem cells, which are then transplanted after the ablation has been completed. The ablation and the transplantation may be performed simultaneously or in a sequential manner. The patient then begins a period of recovery and treatment using chemotherapy and/or radiation. The hope is to achieve a complete remission of the disease with transplantation and the use of appropriate chemotherapy and/or radiation.